MAGCELL® MICROCIRC helps with chemotherapy-induced polyneuropathy (CIPN)

Back to overview

A new double-blind placebo-controlled Phase III study (Rick et al. 2016) underpins results of a preceding Phase II study (Geiger et al. 2015)

MAGCELL® MICROCIRC relieves symptoms of sensory neurotoxicities on hands and feet induced by chemotherapy. A significant improvement compared to the placebo group was shown for the primary clinical end point - nerve conduction velocity of the peroneal nerve in the treatment group at study end (T3). The same applies in respect of the subjectively perceived neurotoxicity strength (CTCAE-Score, one of the other secondary clinical end points). The new finding of the authors is the fact that so far MAGCELL® MICROCIRC is the only non-pharmacological intervention of significant benefit to patients. Read the entire study here.